iosBio is a UK-based biotechnology company developing a ground-breaking oral platform that could revolutionise the way vaccines are manufactured, distributed and delivered. 

Their current focus is an oral vaccine for Covid-19, which has started clinical trials, combined with an oral version of the seasonal influenza vaccine in preclinical studies (“FluVid”) and several further vaccines and therapies currently in discovery. 

First Sentinel helped iosBio raise £8 million of funding and acted as strategic and corporate adviser to the company. 

Visit the website

Clarify Pharma

Biotech and life sciences investor at the forefront of the psychedelics sector.

More Information

Kasei Holdings

Digital asset investment group providing exposure to a variety of cryptocurrencies and related projects.

More Information

NFT Investments

One of the first NFT investment vehicles in the world.

More Information
Contact Us